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Abstract Using a proprietary technology known as the X-ACTTM systemFActive-metering, Cyclone-separator
Technology, a novelmulti-dose inhaler (AirmaxTM) was developed to provide accurate and consistentdosing and a high-
fineparticle fractionofthe drug.Formoterol, present as ablendwithlactosemonohydratewasdelivered fromAirmaxTM
to obtainanominal formoteroldoseof 6 or12 mg.Thedevicesweretestedusinga five-stageliquidimpingerandaunitdose
sampling apparatus, operated under conditions specified in European Pharmacopoeia (2000).Fine-particle dose (FPD)
wasdefinedasthedoseofthe aerosolizeddrugparticleswithanaerodynamicdiametero5 mmandfineparticle fraction
(FPF)was theratio of FPD tothetotalrecovereddose.Doseper actuationwas foundtobe 97.0711.5% labelclaim (LC) or
5.870.7 mg (n=140), and10079.4% LCor1271.1 mg (n=440), for the 6 and12 mg strengths, respectively.Themassmedian
aerodynamic diameter was 2.470.1 mm (n=14), the geometric standard deviation 2.170.1 (n=14), and FPF 44.472.4%
(n=14) for both strengths.Thus, the combination of active metering and cyclone separator produces highly consistent
doses of formoterol thathave a large respirable fraction.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2002.1361, available online at http://www.idealibrary.comon
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Drug delivery to the lung by inhalation has long been re-
garded as the preferred route for the treatment of lung
diseases since itmaximizes therapeutic e¡ects andmini-
mize any side e¡ects by targeting drugs directly to the
sites of actions. Pressurized metered dose inhalers
(pMDI) are still the dominant devices but the Montreal
Protocol and its consequent environmental legislation
have urged the pharmaceutical industry to develop alter-
native devices since the chloro£uorocarbon (CFC) pro-
pellants used in conventional pMDI contribute to the
depletion of atmospheric ozone layer. Another problem
plaguing pMDI is the requirement of coordination be-
tween actuation and inhalation.Manypatients areunable
to operate the devices correctly even after training.
Although such a problem has, to some extent, been
solved by the use of spacer devices and breath-actuated
mechanism, pMDI still have other problems such as
time-dependent dose variation (shaking, priming, dose
tailing) and variable deposition depending on inhalation
manoeuvre (1).There is still environmental concernwithReceived 30October 2001, accepted in revised form11February 2002.
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(HFAs) speci¢cally for HFA-134a due to its degradation
product, tri£uoroacetic acid which is not environmen-
tally friendly (2). Also,HFAs are known to be 2000 times
as potent as carbon dioxide as a ‘‘greenhouse’’ gas. If the
Kyoto Protocol is rati¢ed, then the reduction in green-
house gases may a¡ect the use of HFA propellants in
medicinal aerosols.
Without the use of any propellants, dry powder inha-
lers (DPIs) are environmentally friendly. These are
breath-operated devices and thus overcome the coordi-
nation issue. The dose is released and subsequently dis-
persed by the patient’s inspiratory air£ow. Single-dose
DPIs (Spinhalers, RPR and Rotahalers, Glaxo Well-
come), were introduced approximately 30 years ago but
these have been considered inconvenient and di⁄cult to
use (3). More recently, development has taken place of
devicesholdingmultiplepre-meteredunitdoses (Diskha-
lers and Diskuss,GlaxoWellcome), and reservoir-type
devices, where each dose is metered from bulk during
use (Turbuhalers, Astra Zeneca; Clickhaler, Innovata
Biomed and Easyhalers, Orion). Each device has its
strength and weakness. For example, Turbuhalers typi-
cally delivers up to twice asmuch of themetereddose to
the lungs as Diskuss (4,5).Conversely, lung delivery has
been found to bemore consistent at di¡erent £ow rates
with Diskuss thanTurbuhalers (3,6).The dose indicator
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doses remaining, whereas that for Turbuhalers only
gives an approximate indication that the inhaler is close
to empty.Both devices require thepatient to open a dust
cover and then prime the inhaler before taking a dose
(7,8).Currently, there is hardly any DPI that delivers con-
sistently high doses to the lung.Therefore, it is the aim of
thepresentwork to develop a device that is consistent in
delivering a dose and e⁄cient in generating deeply inspir-
able drug particles.
METHODS
Design concept
Twokeymechanisms are involved in the deliveryof drugs
from multi-dose dry powder inhalers (MDPI) and these
are metering and dispersion. In broad senses, metering
mechanism governs the delivered dosewhilst the disper-
sionmechanism determines the amount of drug that can
reach the lower airways.Therefore, in the development
of AirmaxTM, special attention has been given to these
mechanisms, leading to the invention of an activemeter-
ing and a cyclone-separatorTechnology.
Unlike other inhaler devices that rely on gravity for
dose metering, AirmaxTM uses an air pump to meter
out the precise dose of medication. The dry powder (a
blend ofmedication and the lactose carrier) is contained
in a funnel-shapedbulk powderdrugreservoir, which lies
beneath the air pump.The action of patient’s opening the
mouthpiece cover activates this pump, which in turn ex-
erts a constant air pressure on the powder in the drug
reservoir (Fig.1).The controlled air pressure on the pow-
der ensures that the samevolume of theblendenters theFIG. 1. Schematicdrawing ofthe activemeteringprinciple ofthe Adose cup below the drug reservoir, from one dose to the
next. This precise, consistent ¢lling of the powder into
the dose cup then determines the amount of powder
available for inhalationFand thus assists in accurate
and consistent dose delivery.
After dose metering, the next stage is to ensure that
the drug is separated from the carrier, anddispersed into
primary particles that are small enough to reach the site
of actions in the small airways of the lungs. This is
achieved by AirmaxTM’s unique cyclone separator.When
the patient inhales, air enters AirmaxTM through two
tangential inlets above the mouthpiece; this creates the
cyclonic £ow within the separator in the direction
shown by the arrows in the diagram (Fig. 2).The cyclone
separator is designed to maximize the dispersion and
deaggregation of the drug by means of cyclonic £ows
within the separator. Ramps on its roof are precision
manufactured to induce turbulence and prolong the
length of timewhile the air-borne powdered drug blend
remains in the cyclone. As the drug blend is spun round
inside the separator, the centrifugal and drag forces that
are generated on the particles, the turbulence of the air-
stream and collisions of particles with the cyclone walls
all act together tomaximize break-up of drug agglomer-
ates and separation of the drug from the lactose carrier.
Once the particles in the blend have been separated,
the smaller drug particles are released into the mouth-
piece ¢rst, while the larger lactose particles remain in
the cyclone separator.The separated dose leaves the cy-
clone and is delivered to the user via the mouthpiece,
fromwhere the ¢ne particles are delivered to the lungs.
The larger lactoseparticles are emitted from the cyclone
next; they stay mainly in the mouth and throat, from
where they are swallowed. The total metered dose isirmaxTMdevice.
FIG. 2. Schematic representation ofthe cyclone and air£owinthe AirmaxTMdevice.
FORMOTEROLINANOVELINHALER 399emitted. In this way, the cyclone separator technology
ensures e¡ective drug dose delivery to the lung.
The air pump and dosemetering are triggeredby a se-
quence controller inside AirmaxTM, operated by the pa-
tients’ opening the mouthpiece cover. The sequence
controller also automates the transfer of the metered
dose from the ‘‘metering position’’ to the ‘‘inhale posi-
tion’’, and the indexing of the dose counter.The mechan-
ism has been designed to be robust and resistant to
mishandling. This simple automated system means that
AirmaxTM is easy to use.
Measurement of air resistance
Air resistance is an important characteristic for DPI
since it determines the inspiratory £ow rate achievable
by patients.The air £ow rate in turn governs drug deliv-
ery from the device to the lung. It is therefore essential
to control device air resistance so as to produce ade-
quate air £ow rate by themajority of patients after inha-
lation with ‘‘comfortable’’ e¡ort normally corresponding
to a pressure drop of 4kPa (40.8 cmH2O) across the de-
vice (9). In order to quantify air resistance, air £ow rates
from AirmaxTM at di¡erent pressure drops between 1
and 5kPa were determined by attaching AirmaxTM to a
dose uniformity sampling unit (DUSA,Copley,U.K.) that
has a manometer (RS,U.K.) attached to its port tomea-
sure pressure drop. After the pressure drop was ad-
justed to the pre-determined value, the £ow rate across
the DUSAwasmeasured by a digital £owmeter (Copley,
U.K.). Ten devices were tested ad the mean £ow rate at
each pressure dropwas utilized to calculate the air resis-
tance of the device.Formulation development
Formoterol, a long acting beta-2 agonist bronchodilator,
has been delivered by a unit-dose, capsule-based DPI
(Foradils, Novartis Pharma S.A.) to deliver a nominal
dose of 12mg formoterol fumarate (10). In order for the
drug to gain access to the lower airways, a prime re-
quirement is that the drugparticleshave an aerodynamic
diameter between1and 5mm (11). Particles of such a size
range are notoriously di⁄cult to £ow and disperse due
to its highly cohesive nature (12).The micronized drug is
often mixed with a coarse carrier such as lactose to im-
prove powder £ow and dispersion properties (13).Thus,
for administration via AirmaxTM, micronized formoterol
was blended with lactose. During development, various
grades of lactose were evaluated to obtain formulations
with optimal pharmaceutical performance.
Emittedmass
The through life emitted mass from AirmaxTM was as-
sessed gravimetrically using the Emitted Dose Collector
System (EDCS, theTechnology Partnership).The perfor-
mance of AirmaxTM was also compared to that of a con-
ventional multi-dose dry powder inhaler (Oxis
Turhuhalers). For both inhalers, single dose was drawn
into a collection ¢lter at an air£ow rate of 60 l/min for
4 s.The increase in the weight of the ¢lter was taken to
represent themass delivery of each actuation.
Dose content uniformity (DCU)
Doseper actuation (DPA) was testedusing conditions as
speci¢ed in European Pharmacopoeia (2000). Thus, 10
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device life, were ¢red separately into a Dose Uniformity
Sampling Apparatus (Copley,U.K.) at Q, a £ow rate that
generated a pressure drop of 4kPa across the device (ca.
69 l/min). After 4 litres of air hadbeen drawn through the
device, the drug that was collected was recovered and
analyzed using a validated high performance liquid chro-
matography (HPLC) method. Whilst DPA results have
routinely been assessed using European Pharmacopoeia
(2000) speci¢cations for DCU, content uniformity re-
sults have been re-calculated as percentage of label
claim.
Aerodynamic particle-size distribution
This was assessed using a ¢ve-stage liquid impinger
(MSLI, Copley, U.K.) operated at European Pharmaco-
poeial (2000) conditions. A number of doses (20 for
6mg devices but 10 for 12mg devices) were actuated into
an MSLI, each drawn by 4 l of air at Q.The dose number
was determinedby the sensitivityof assaymethods.Each
devicewas tested at beginning and end of device life.The
drugdeposited at each stage ofMSLIwas thenrecovered
separately and assayed by a validated HPLCmethod.
Total recovered dose (TRD) was the sum of drug col-
lected from the induction port and at all ¢ve stages of
the impinger. Fine particle dose (FPD) was de¢ned as
the dose of the aerosolized drug with particle size o
5mm.Fine particle fraction (FPF) was the percentage ra-
tio of FPD toTRD. Results were also expressed as Mass
Median Aerodynamic Diameter (MMAD) and Geo-
metric Standard Deviation (GSD) of the particles col-
lected in the MSLI. It is again impossible to report all
aerodynamice data but great caution has been taken toFIG. 3. Mass delivery froma12 mg formoterol AirmaxTM and a12 minclude data that best re£ect the performance of these
products.
RESULTS
Air resistance
Plotting the square root of pressure drop (P) against vo-
lumetric £ow rate (Q) resulted in a straight line with in-
tercept of 0, a slope of 0.0924 and R2=0.996.
Since P0.5 =RQ (14) where R is the air resistance.
The air resistance takes the value of the slope, i.e. 0.0924
(cmH2O)
0.5 min/l.
Emittedmass
Figure 3 shows typical mass-delivery pro¢les from the
formoterol AirmaxTM and OxisTurbuhalers.Clearly, the
AirmaxTM has a highly consistent delivery of drug with a
RSD of mass delivery of ca. 2%. In comparison,OxisTur-
buhalers appears to be less consistent andhas anRSD of
ca.12% inmass delivery.
Dose content uniformity
The overall mean DPA (7SD) of 6mg formoterol Air-
maxTM was 97.0711.5% label claim (LC) or 5.870.7mg
(n=140).Each individual deviceproducedmeanDPAwith-
in 85^115% LC.The majority of DPA’s (95%) were within
80^120% LC. Five DPA’s (3.6%) were outside of 80^120%
LC, but within 75^125% LC. Two DPA (1.4%) fell out of
75^125% LC, but within 65^135% LC.The spread of DPA
values is shown in Fig. 4.g OxisTurbuhalers.
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AirmaxTMwas10079.4% LCor12.071.1mg (n=440). Each
individual device producedmean DPA, which was within
85^115% LC. The majority (98%) of DPA’s were within
80^120% LC. Seven DPA’s (1.6%) were outside of 80^
120% LC, but within 75^125% LC.Two DPA’s (0.4%) were
marginally higher than 125% LC, but less than 135% LC.
The spread of DPAvalues is shown in Fig. 5.
Aerodynamic particle-size distribution
From Table 1, it can be seen that ¢ne-particle fraction
measured between 41 and 49% for both strengths, and
there was no di¡erence in the performance at the start
and end of device life.Themassmedian aerodynamic dia-FIG. 4. Dose distribution in % LCfromthe 6 mg formoterol Airm
FIG. 5. Dose distribution in % LCfromthe12 mg formoterol Airmmeter variedbetween 2.2 and 2.6mmand the geometric
standard deviation between 1.9 and 2.0. Total recovered
dose was close to LC, and all devices delivered in excess
of the nominal number of actuations.
Stability studies
Extensive stability studies are being performed on these
productsunder InternationalConference onHarmonisa-
tion (ICH) conditions. Devices are stored at several or-
ientations, under various conditions including 251C/60%
RH, 301C/60%RHand 401C/75%RH, either in their ¢nal
packaged form or completely unpacked to mimic the
conditions when the devices are used by patients. Data
from these studies support a shelf life of at least 24axTM (n=140).
axTM (n=440).
TABLE 1. Aerodynamic particle-size distribution of for-
moterol from AirmaxTM at Q (ca.69 l/min)
Test
parameters
Device strength/no. of actuations (device no.)
6 mg/60 (n=4) 12 mg/60 (n=3)
Start of inhaler
TRD (mg) 6.2270.67 11.4170.32
MMAD (mm) 2.4070.14 2.4070.10
GSD 2.2070.00 2.1070.00
FPD (mg) 2.9070.41 4.9770.21
FPF (%TRD) 46.572.5 43.371.5
End of inhaler
TRD (mg) 5.8770.05 12.3370.91
MMAD (mm) 2.3570.06 2.4070.10
GSD 2.1370.05 2.1370.06
FPD (mg) 2.5570.35 5.4770.46
FPF (% TRD) 43.372.6 44.371.2
TABLE 2. Air resistance of AirmaxTM compared with
othercommercial DPIs (9)
Inhalation devices Air resistance
(cmH2O)
0.5min/l
Rotahaler 0.040
Spinhaler 0.051
ISF inhaler 0.055
Diskhaler 0.067
Airmax 0.092
Turbuhaler 0.100
Inhalator M 0.180
402 RESPIRATORYMEDICINEmonths for inhalers packed in moisture-proof foil
pouches and in-use life of at least 3 months after packa-
ging has been removed.
DISCUSSION
AirmaxTM demonstrated reproducible mass delivery of
the blend, leading to consistent delivery of the drug.
Thus, the active metering principle has successfully pro-
duced precise and repeatable delivery of the drug. Drug
delivery from AirmaxTM is close to the LC and the per-
formance ismaintained throughout life.
The second element of the technology is the cyclone
separator.This is constructed to e⁄ciently disperse the
drug in order to provide a high lung delivery.Formoterol
would be expected to be a di⁄cultmolecule to disperse
due to the small dose compared to the mass of lactose
carrier. However, for both strengths ¢ne-particle frac-
tion measured over 40% with an MMAD of 2.2^2.6mm.
Thus, almost half of the delivered dose had an aerody-
namic particle sizeo5mm, suggesting that AirmaxTM is
highly e⁄cient in generating deeply inspirable drugparti-
cles. Moreover, there was little di¡erence in the intra-
and inter-deviceperformance, an indication of consistent
pharmaceutical performance.
The AirmaxTM exhibited a moderate resistance to in-
halation air£ow with speci¢c resistance similar to that of
Turbuhalers (Table 2). As expected, it has also been
shown that the air resistance through AirmaxTM is inde-
pendentof the type andmass of theblends in thehopper.
The air resistance of AirmaxTM is close to the range of
0.06^0.09, which is preferred by the patients (9).
As well as delivering a good technical performance, it
is important that an inhaler is attractive, convenient, ro-bust and as simple and foolproof in use as possible. Air-
maxTM has been designed to have a familiar shape, not
unlike the pMDI that most patients will have used. It is
compact, and simple and intuitive to operate: opening
the mouthpiece cover is all that is necessary to prepare
a dose for inhalation, and after taking the dose closing
the mouthpiece cover again makes the device ready for
the nextuse. A dose counter with a generously sizeddis-
play provides a clear and precise indication of the num-
ber of doses remaining and gives extra warning as the
inhaler approaches empty. All of these functions are op-
erated from themovementof themouthpiece cover by a
sequence controller inside the device, which coordinates
metering of the dose, transfer to the inhalation position
and advancement of the dose counter. Testing demon-
strated that the sequence controller is una¡ectedby op-
eration to ¢ve times the normal device life.
In conclusion, active metering and cyclone separator
technology are the keys for the excellent performance
characteristics of AirmaxTM, including a highly accurate
and consistentdose of formoterol and a large proportion
of the delivered dose consisting of ¢ne (respirable)
particles.
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